Induced pluripotent stem cells (iPSC) have tremendous potential to treat degenerative conditions and genetic diseases. MyoPAXon Bio is pioneering a stem cell-based therapy, comprising human skeletal myogenic progenitors derived from pluripotent stem cells, to replenish diseased muscle with normal functional muscle fibers (and muscle stem cells) enabling long-term muscle maintenance. MyoPAXon Bio aims to regenerate muscle lost to a variety of conditions, including various devastating muscular dystrophies, such as DMD. MyoPAXon Bio has extensive pre-clinical validation for a method to generate engraftable skeletal myogenic progenitors from pluripotent stem cells, and the implementation of this method under cGMP conditions. MyoPAXon Bio is seeking a business exec to co-found the business with the UMN and the research team.
Valerian Materials is leading the way in renewable, degradable, and recyclable polymers. The biomass derived materials have applications as resilient foams and elastomers as well as tough plastics and thermosets. The principal technology relies on efficient and economical fermentation of sugar to give small molecules that can be catalytically converted to polymers in high yields at low temperatures with controlled molar mass. The versatility of the polymer platform is a key aspect and allows for broad penetration in a wide variety of industries. Valerian Materials is seeking a business executive to join the company and lead the development and execution of the next stage of the business growth.
Nearly 1.6 million Americans have Type 1 Diabetes (T1D), an autoimmune class of diabetes. Additionally, ~3.2 million Americans develop latent autoimmune diabetes of adults (LADA). For T1D or LADA patients, immunotherapy promises a path to reprogram the immune system such that it no longer attacks and destroys insulin-producing beta cells in the pancreas. SermAb Biologics is developing a monoclonal antibody therapy against serpinB13. SermAb Biologics focuses on the discovery that tissue regeneration is stimulated by blocking serpinB13 and restoring the activity of its protease target. The second advantage is that our antibody to serpinB13 suppresses inflammation, increases beta-cell proliferation, and delays the onset of diabetes. Thus, by using a single reagent that regulates the balance between serpin inhibitor and protease, we can simultaneously suppress the inflammatory response while promoting regenerative changes in the pancreas and other tissues expressing serpinB13.
One of the most worrisome complications of the current global pandemic of COVID-19 is acute respiratory distress syndrome (ARDS), which is characterized by excess inflammation and fluid in the lung and has high mortality despite years of study. Research has indicated that more than 40% of the individuals hospitalized with severe COVID-19 develop ARDS and over half of those cases are fatal. A team of researchers at the University of Minnesota with decades of research knowledge surrounding lung diseases have developed a novel and promising treatment approach for ARDS utilizing Liothyronine (T3), a synthetic form of thyroid hormone that already has FDA approval. Application of T3 to injured lungs has been shown to speed fluid clearance in animal models and clinical trials are already underway to validate translation to humans suffering with ARDS.